Overview

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Cilastatin
Imipenem
Minocycline
Tigecycline